About Sentien Biotechnologies
Sentien Biotechnologies is a Healthcare company based in Lexington (United States) founded in 2008 by Biju Parekkadan and Brian Miller. Stem cell-based devices for acute organ failure are developed. Sentien Biotechnologies has raised $13.05 million across 3 funding rounds from investors including HHS, Portage Biotech and Boehringer Ingelheim Venture Fund. The company has 7 employees. Its chief executive, as recorded, is Brian Miller. Its focus areas include Life Sciences, Nephrology, Medical Devices and Therapeutic Devices. Its legal entity is SENTIEN BIOTECHNOLOGIES INC. Its competitors include Aclaris Therapeutics, Escient Pharmaceuticals and Nimbus Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Sentien Biotechnologies was founded in 2008 in Lexington, United States, as a pre-clinical regenerative medicine company. Cell-based therapies for acute organ failure are being developed, including proprietary cell compositions. The lead product, Sentinel, is designed to address severe acute kidney injury by supplementing patient blood with mesenchymal stem cell-derived secretions during dialysis. Integration with existing dialysis equipment is incorporated into the device design.
- Headquarters Lexington, United States
- Employees 7
- Founders Biju Parekkadan, Brian Miller
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website sentienbiotech.com
- Social LinkedIn X
- Legal Name Sentien Biotechnologies Inc
- Total Equity Funding$13.05M (USD)
in 3 rounds
- Latest Funding Round$12M (USD), Series A
Apr 2017
- InvestorsHHS
& 6 more
- Employee Count7
Funding Insights of Sentien Biotechnologies
Sentien Biotechnologies has successfully raised a total of $13.05M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $12 million completed in April 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.05M
- Total Rounds 3
- Last Round Series A — $12M
- First Round $565,011
(Jun 2010)
- Investors Count 7
All 3 funding rounds of Sentien Biotechnologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2017 | $12M | Series A | – | Boehringer Ingelheim Venture Fund, Mission BioCapital | |
| Aug 2015 | $1.05M | Series A | – | – | |
| Jun 2010 | $565,011 | Grant | – | – |
7 investors in total: 7 institutional.
Investors in Sentien Biotechnologies
Sentien Biotechnologies has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Portage Biotech and Boehringer Ingelheim Venture Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund. | boehringer-ingelheim-venture.com | |||
Chiesi Ventures is focused on venture capital for rare diseases. | chiesiventures.com | Boston, United States | ||
| mblvc.co.jp | ||||
Seed stage investments are made in life sciences and healthcare. | 2010 | massmedangels.com | Boston, United States | |
Investments in life science startups are made by Mission BioCapital. | missionbiocapital.com | San Francisco, United States | ||
Therapeutics based on Cell Permeable Peptide Platform | 2013 | portagebiotech.com | Tortola, United Kingdom | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Sentien Biotechnologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sentien Biotechnologies
4 people are tracked at Sentien Biotechnologies (3 in leadership, 1 in team); the tracked headcount is 7.
| Name | Role | Group |
|---|---|---|
Biju Parekkadan | Co-Founder | Leadership |
Brian Miller | Co-Founder & CEO | Leadership |
Rita Barcia | Vice President Research And Development | Leadership |
Monique Gregory | Researcher | Team |
Complete people profiles for Sentien Biotechnologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Sentien Biotechnologies
3 dated milestones of Sentien Biotechnologies across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Sentien Biotechnologies is founded.
- Funding First funding round of $565K.
- Funding Latest funding round, Series A, of $12.0M.
Competitors of Sentien Biotechnologies
Sentien Biotechnologies has 3 listed competitors in our database, 3 of them funded. They include Aclaris Therapeutics, Escient Pharmaceuticals and Nimbus Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. |
Detailed competitors of Sentien Biotechnologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sentien Biotechnologies
Websites that share an audience with Sentien Biotechnologies (sentienbiotech.com).
Websites whose visitors overlap most with Sentien Biotechnologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Sentien Biotechnologies (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sentien Biotechnologies
Complete news archive for Sentien Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sentien Biotechnologies
Sentien Biotechnologies was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Sentien Biotechnologies is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Brian Miller is the CEO of Sentien Biotechnologies, as recorded in our data. They have also founded this company.
Sentien Biotechnologies is a funded company, having raised a total of $13.05M across 3 funding rounds to date. The company's 1st funding round was a Grant of $565.01K, raised on Jun 2010.
Sentien Biotechnologies has 7 employees.
Sentien Biotechnologies was founded in 2008 in Lexington, United States, as a pre-clinical regenerative medicine company. Cell-based therapies for acute organ failure are being developed, including proprietary cell compositions. The lead product, Sentinel, is designed to address severe acute kidney injury by supplementing patient blood with mesenchymal stem cell-derived secretions during dialysis. Integration with existing dialysis equipment is incorporated into the device design.
Sentien Biotechnologies's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Aclaris Therapeutics.
Sentien Biotechnologies has 7 investors. Key investors include HHS, Portage Biotech, Boehringer Ingelheim Venture Fund, Chiesi Ventures, and MBL Venture Capital.
Sentien Biotechnologies operates through Sentien Biotechnologies Inc.